Antithrombotic therapy in ST-segment elevation myocardial infarction

Bibliography

• Kushner FG, Hand M, Smith SC Jr, 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Kini AS, Chen VH, Krishnan P, Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2008;156:513-19
   PubMed Web of Science ®Google Scholar
• Rao SV, Cohen MG, Kandzari DE, The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol 2010;55:2187-95
   PubMed Web of Science ®Google Scholar
• ten Berg JM, 't Hof AW, Dill T, Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010;55:2446-55
   PubMed Web of Science ®Google Scholar
• Ellis SG, Tendera M, de Belder MA, Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-17
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway? Circulation 2010;121:739-41
   PubMedGoogle Scholar
• Thiele H, Schindler K, Friedenberger J, Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57
   PubMed Web of Science ®Google Scholar
• Deibele AJ, Jennings LK, Tcheng JE, Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010;121:784-91
   PubMed Web of Science ®Google Scholar
• Mehran R, Lansky AJ, Witzenbichler B, Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Dangas G, Mehran R, Guagliumi G, Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009;54:1438-46
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised trial. Lancet 2010;376(9748):1233-43
   Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Chen J, Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA 2009;302:767-73
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kereiakes DJ, Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703
   PubMed Web of Science ®Google Scholar
• Stone GW, White HD, Ohman EM, Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH, Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-88
   PubMed Web of Science ®Google Scholar
• White HD, Braunwald E, Murphy SA, Enoxaparin vs unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 2007;28:1066-71
   PubMed Web of Science ®Google Scholar
• Gibson CM, Murphy SA, Montalescot G, Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2238-46
   PubMed Web of Science ®Google Scholar
• Montalescot G, Ellis SG, de Belder MA, Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv 2010;3:203-12
   PubMedGoogle Scholar
• Montalescot G, Cohen M, Goldstein P, ATOLL-An international randomized study comparing IV enoxaparin to IV UFH in primary PCI for ST-elevation myocardial infarction. Proceedings of the Hot Line II- Coronary artery disease-European Society of Cardiology Congress 2010; Stockholm, Sweden-August 30, 2010-Hotline session
   Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30
   PubMed Web of Science ®Google Scholar
• Vlaar PJ, Svilaas T, van der Horst IC, Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915-20
   PubMed Web of Science ®Google Scholar
• Svilaas T, Vlaar PJ, van dH, Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-67
   PubMed Web of Science ®Google Scholar
• Thiele H, Wohrle J, Neuhaus P, Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010;159:547-54
   PubMed Web of Science ®Google Scholar
• Gu YL, Fokkema ML, Kampinga MA, Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Circulation 2010;122:2709-17
   PubMed Web of Science ®Google Scholar